A market research firm is forecasting 7.5% annual growth for limb prosthetics. That number is an investment signal, not a coverage report.

A market research report cited by EIN News this week projects the global limb prosthetics sector at a 7.5% compound annual growth rate. Reports formatted this way — CAGR headline, market size projection, list of dominant players — are a standard product of the market research industry. They appear regularly, they are picked up by trade and business press, and they are genuinely useful to a specific audience. That audience is not amputees.

Understanding what these reports measure — and what they do not — matters for anyone trying to read the prosthetics industry landscape as a patient or an access advocate rather than as an investor.

What a CAGR forecast actually is

A compound annual growth rate projection is a modeling output, not a measurement of what has happened. A market research firm takes a baseline market size estimate — total revenue across all transactions in a defined product category — and applies an assumed growth rate forward across a defined time horizon, typically five to ten years. The result is an endpoint: “the limb prosthetics market will reach $X billion by year Y.”

The CAGR is the annualized rate that gets you from the current baseline to the projected endpoint. At 7.5% compounding, a market roughly doubles in about ten years.

What that model includes: revenue from device sales, components, and in some methodologies, related services and repair. What it does not include: whether revenue growth reflects more devices reaching more people, or higher prices for the same volume of devices reaching the same people, or a shift toward premium-tier products in markets that already have high penetration.

The distinction matters enormously from an access standpoint. A market can grow robustly at 7.5% annually while the population of people who cannot obtain a prosthetic device stays largely unchanged — if the growth is concentrated in high-value device tiers, in better-insured patient segments, or in geographic markets that already have relatively high coverage rates.

What is actually driving projected growth

Market research reports in this sector tend to identify three categories of growth driver, and they are worth reading carefully.

Aging demographics and diabetes prevalence. The global burden of lower-limb amputation is tied closely to diabetes-related peripheral vascular disease, which increases in absolute terms as populations age and as metabolic disease rates climb. This is a volume driver — it represents more people who need prosthetic devices. It does not, on its own, tell you how many of them will receive one: access to post-amputation rehabilitation, prosthetic fitting, and device coverage is unevenly distributed both within and across countries.

Technological advancement. Higher-function prosthetic components — microprocessor-controlled knees and ankles, myoelectric upper-limb systems, osseointegrated devices — carry higher price points. As these categories expand, they increase average transaction value in markets where they are reimbursable. This is a price and product-mix driver, not simply a volume driver. It can lift market size statistics without expanding the population of device users at all.

Geographic expansion in lower- and middle-income markets. A portion of projected global growth reflects manufacturers and distributors entering or expanding in markets like India, Brazil, and Southeast Asia, where current device penetration is low relative to need. Earlier this week, Motorica announced an exclusive distribution arrangement for TEHLIN’s lower-limb technologies in India — the kind of commercial mechanism that a market analyst would count as market expansion. Whether that expansion reaches the millions of people in those countries who currently have unmet prosthetic need depends on procurement channels, pricing structure, and local coverage policy — none of which distribution alone resolves.

Who these reports are built for

Market research reports of this format exist primarily for three audiences: investors evaluating the sector, manufacturers benchmarking their position against projected market size, and procurement and policy analysts at institutional purchasers. They are bought, not freely distributed, and their value to those audiences is real.

For an investor, a 7.5% CAGR projection in a medical device sector with strong underlying demographic demand is a useful framing of long-term opportunity. For a manufacturer like Ottobock — which raised its own growth guidance this week — it provides external validation of the market context the company is operating in. For a national health ministry or a large insurer modeling future device expenditure, it anchors procurement planning.

None of those uses is the same as knowing whether prosthetic access is improving for the people who need it.

What the CAGR does not measure

The metrics that would answer the access question are different ones: what share of people who lose a limb receive a prosthetic device within a clinically meaningful timeframe; what share of people fitted with devices get regular follow-up and replacement when components wear; what share of denied claims are overturned on appeal; how long, on average, prior authorization takes from submission to decision.

Those are not metrics that appear in market size reports, because they are not revenue metrics. They are outcome and access metrics, and they require a different data infrastructure — claims data, patient-reported outcomes, wait time tracking, denial rate audits — to measure. Most of that data is either proprietary, not systematically collected, or not publicly reported at a level that allows comparison across payers and markets.

The 7.5% CAGR projection can be true — meaning the global limb prosthetics market does grow at roughly that rate over the measurement period — while the access gaps that practitioners and advocates point to remain stubbornly in place. A growing market and an equitably accessible market are not the same thing, and market research methodology is not designed to distinguish between them.

The next useful question

When a market forecast like this circulates, the useful follow-up is: what part of projected growth is volume, what part is price, and in which markets?

The answer to that question — if it is available — tells you something about whether the sector’s financial growth is likely to reach people with unmet need, or primarily to deepen what is already available to people who already have access.

Market research reports are not the right source for that answer. Clinical outcomes data, payer policy changes, prior authorization approval rates, and coverage expansion decisions — those are the signals worth tracking if access is the question.

---

Amputee News does not provide individualized medical, coverage, or device-fitting advice. References to market research reports and industry forecasts are drawn from trade and business press coverage and do not constitute endorsement of any company, product, or methodology. Market projections reflect modeling assumptions and are subject to the limitations of their data sources and methodologies.